CD73 Antikörper (full length) (Biotin)

Produktnummer ABIN7877582

Dieser Maus Monoklonal Antikörper detektiert spezifisch CD73 in WB, FACS, IF, ELISA und IHC (p). Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für CD73 Antikörper (full length) (Biotin) (ABIN7877582)

Target: CD73 (NT5E) (5'-Nucleotidase, Ecto (CD73) (NT5E))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD73 Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: NT5E-2646

Produktdetails anti-CD73 Antikörper (Biotin)

Bindungsspezifität: full length

Verwendungszweck: CD73 Antibody

Aufreinigung: Protein G affinity chromatography

Immunogen: Recombinant full-length human NT5E protein was used as the immunogen for the CD73 antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the CD73 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: 0.1 mg/mL with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the CD73 antibody at 2-8oC (up to one month) or aliquot and store at -20oC (longer term).

Details zu CD73

Target: CD73 (NT5E) (5'-Nucleotidase, Ecto (CD73) (NT5E))

Andere Bezeichnung: CD73

Hintergrund: CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies.

UniProt: P21589

Pathways: Synaptic Membrane, Ribonucleoside Biosynthetic Process